SCHEMBL2434490

SCHEMBL2434490

Cc1noc(C)c1C(=O)Nc1ccc(-c2cc(N(C(=O)C3CCC(C)CC3)C(C)C)c(C(=O)O)s2)cc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.41
ITGB1 P05556 1/20 0.39
ITGA4 P13612 1/20 0.39
PTGS2 P35354 1/20 0.38
CRACR2A Q9BSW2 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
TP53 P04637 3/20 0.37
GAA P10253 2/20 0.37
ALDH1A1 P00352 2/20 0.37
KMT2A Q03164 2/20 0.37
NPY2R P49146 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
AGTR1 P30556 1/20 0.36
MEN1 O00255 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2427836 1.00 GFER (0.41) GFERITGB1ITGA4PTGS2CRACR2A
SCHEMBL2434510 0.87 RAB9A (0.41) GFERTP53ALDH1A1KDM4EMAPT
SCHEMBL2431289 0.87 RAB9A (0.41) GFERTP53ALDH1A1KDM4EMAPT
SCHEMBL2432524 0.87 KMT2A (0.41) TP53KMT2AKDM4EMEN1
SCHEMBL2432516 0.87 KMT2A (0.41) TP53KMT2AKDM4EMEN1
SCHEMBL2431809 0.86 CRACR2A (0.40) CRACR2ATP53AGTR1
SCHEMBL2430581 0.86 DGAT1 (0.33) KMT2AMEN1
SCHEMBL2430585 0.86 DGAT1 (0.33) KMT2AMEN1
SCHEMBL2431812 0.86 CRACR2A (0.40) CRACR2ATP53AGTR1
SCHEMBL2428556 0.86 HSD17B10 (0.41) ALDH1A1KMT2AMAPTMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2086966-B1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2011-09-14 EP claimed
US-20090274655-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION 2009-11-05 US claimed
EP-2086966-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SmithKline Beecham Corporation (US) 2009-08-12 EP claimed
WO-2008059042-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2008-05-22 WO claimed
EP-2086966-B1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2011-09-14 EP disclosed
US-20090274655-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION 2009-11-05 US disclosed
EP-2086966-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SmithKline Beecham Corporation (US) 2009-08-12 EP disclosed
WO-2008059042-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274655-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS EIF2AK2, HAVCR2, GTF3C2 GFER 2744/4885ITGB1 2565/4885ITGA4 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.